Three CD19 CART products have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)], for the treatment of R/R aggressive B-cell lymphomas, including DLBCL, high-grade B-cell lymphoma, transformed follicular lymphoma, and primary mediastinal B-cell lymphoma, after ≥ 2 prior lines of systemic therapy, and they show high response rates with durable remissions (9–11). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.